New Jersey Attorney General Targets Industry Ties To Clinical Investigators
This article was originally published in The Gray Sheet
Executive Summary
The attorney general of New Jersey is going after the device industry for failures to disclose possible financial conflicts of interest with clinical trial investigators, and wants FDA to strengthen its enforcement, as well
You may also be interested in...
Clinical Investigators' Financial Disclosures Might Become Public – Guidance
FDA is signaling greater readiness to publicly disclose what was once considered proprietary information on the financial ties of clinical trial investigators.
Clinical Investigators' Financial Disclosures Might Become Public – Guidance
FDA is signaling greater readiness to publicly disclose what was once considered proprietary information on the financial ties of clinical trial investigators.
New Jersey Office Wants Physicians To Report Industry Financial Ties
New Jersey physicians should publicly report their financial ties with device and pharmaceutical firms as a condition of renewing their medical licenses, the state's Division of Consumer Affairs advised in a Dec. 4 report to New Jersey's Attorney General Anne Milgram